| Predicate |
Object |
| contentType |
Journal Article |
| issn |
1758-8359 |
| pageRange |
1758835920916000- |
| publicationName |
Therapeutic Advances in Medical Oncology |
| startingPage |
1758835920916000 |
| hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_855276b36d1ea379d6a73dab5b988d0d |
| bibliographicCitation |
Wu B, Ma F. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. Ther Adv Med Oncol. 2020;12():1758835920916000. PMID: 32426048; PMCID: PMC7222249. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fa651bd4e197ab81f03214bc02897370
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_366509e3b963175ba944e1a562d09922 |
| date |
202001 |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/32426048
https://doi.org/10.1177/1758835920916000
https://pubmed.ncbi.nlm.nih.gov/PMC7222249 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1758-8359
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/37603 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7a0153350cba31da4ce6bfa8f8c68f72
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11451 |